Conference
Benralizumab Significantly Reduced Oral Corticosteroid Dosages and Asthma Exacerbation Rates for Patients With Severe, Uncontrolled Asthma: Results of the ZONDA Phase III Trial
Authors
Nair P; Wenzel SE; Rabe K-F; Bourdin A; Lugogo N; Kuna P; Barker P; Sproule S; Ponnarambil S; Goldman M
Volume
195
Pagination
pp. a4678-a4678
Publication Date
January 1, 2017
DOI
10.1164/ajrccm-conference.2017.195.1_meetingabstracts.a4678
Conference proceedings
American Journal of Respiratory and Critical Care Medicine
Issue
Supplement_1
ISSN
1073-449X
